



PTO/SB/08A (01-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Sheet 1 of 3

**COMPLETE IF KNOWN**

|                        |                |
|------------------------|----------------|
| Application Number     | 10/576,142     |
| Filing Date            | April 18, 2006 |
| First Named Inventor   | ARENDT, et al. |
| Art Unit               | Unassigned     |
| Examiner Name          | Unassigned     |
| Attorney Docket Number | 4121-180       |

**U.S. PATENT DOCUMENTS**

| Examiner Initials* | Cite No. | Document Number    | Publication Date<br>MM-DD-YYYY | Issue Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document |
|--------------------|----------|--------------------|--------------------------------|--------------------------|--|
|                    | AA       | US-2002/0081635 A1 | June 27, 2002                  |                          | Thomas et al.                                      |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |
|                    |          | US-                |                                |                          |  |

|                    |                     |                 |            |
|--------------------|---------------------|-----------------|------------|
| Examiner signature | /Stacey Macfarlane/ | Date Considered | 07/24/2008 |
|--------------------|---------------------|-----------------|------------|

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>1</sup> All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. § 1.98(a)(3)(i), according to MPEP 609 III A(3).

|  |                          |                |
|--|--------------------------|----------------|
| <b>INFORMATION<br/>DISCLOSURE STATEMENT<br/>BY APPLICANT</b><br><br>Sheet 2 of 3 | <b>COMPLETE IF KNOWN</b> |                |
|  | Application Number       | 10/576,142     |
|  | Filing Date              | April 18, 2006 |
|  | First Named Inventor     | ARENDR, et al. |
|  | Art Unit                 | Unassigned     |
|  | Examiner Name            | Unassigned     |
|  | Attorney Docket Number   | 4121-180       |

| NON-PATENT LITERATURE DOCUMENTS |          |  |                |
|---------------------------------|----------|--|----------------|
| Examiner Initials*              | Cite No. | Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published                  | T <sup>2</sup> |
|                                 | AB       | ARENDR, T., ET AL., Aberrancies in signal transduction and cell cycle related events in Alzheimer's disease, Journal of Neural Transmission, 1998, Page(s) 147-158, Supplement 54, Springer-Verlag Wien, New York  |                |
|                                 | AC       | ARENDR, THOMAS, ET AL., Activated Mitogenic Signaling Induces a Process of Dedifferentiation in Alzheimer's Disease That Eventually Results in Cell Death, Annals New York Academy of Sciences, Page(s) 249-255  |                |
|                                 | AD       | ARENDR, THOMAS, Alzheimer's disease as a loss of differentiation control in a subject of neurons that retain immature features in the adult brain, Neurobiology of Aging, 2000, Page(s) 783-796, Elsevier Science Inc.   |                |
|                                 | AE       | ARENDR, T., ET AL., Increased Expression and Subcellular Translocation of the Mitogen Activated Protein Kinase Kinase and Mitogen-Activated Protein Kinase in Alzheimer's Disease, Neuroscience, 1995, Page(s) 5-18, Volume 68, Number 1, Elsevier Science Ltd., Great Britain |                |
|                                 | AF       | ARENDR, THOMAS, ET AL., Neuronal activation of Ras regulations synaptic connectivity, European Journal of Neuroscience, 2004, Page(s) 2953-2966, Volume 19, Federation of European Neuroscience Societies  |                |
|                                 | AG       | ARENDR, T., ET AL., Neuronal expression of cyclin dependent kinase inhibitors of the INK4 family in Alzheimer's disease, Journal of Neural Transmission, 1998, Page(s) 949-960, Volume 105, Springer-Verlag, Austria   |                |
|                                 | AH       | GÄRTNER, M., ET AL., Letter to Neuroscience Elevated Expression of p21 <sup>ras</sup> is an Early Event in Alzheimer's Disease and Precedes Neurofibrillary Degeneration, Neuroscience, 1999, Page(s) 1-5, Volume 91, Number 1, Elsevier Science Ltd., Great Britain           |                |

|                    |                     |                 |            |
|--------------------|---------------------|-----------------|------------|
| Examiner signature | /Stacey Macfarlane/ | Date Considered | 07/24/2008 |
|--------------------|---------------------|-----------------|------------|

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>2</sup> Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Sheet 3 of 3

## *COMPLETE IF KNOWN*

|                        |                |
|------------------------|----------------|
| Application Number     | 10/576,142     |
| Filing Date            | April 18, 2006 |
| First Named Inventor   | ARENDT, et al. |
| Art Unit               | Unassigned     |
| Examiner Name          | Unassigned     |
| Attorney Docket Number | 4121-180       |

## **NON-PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. | Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published  | T <sup>2</sup> |
|--------------------|----------|--|----------------|
|                    | AI       | HOLZER, M., ET AL., Activation of Mitogen-Activated Protein Kinase Cascade and Phosphorylation of Cytoskeletal Proteins After Neurone-Specific Activation of P21RAS. I. Mitogen-Activated Protein Kinase Cascade, Neuroscience, 2001, Page(s) 1031-1040, Volume 105, Number 4, Elsevier Science Ltd., Great Britain        |                |
|                    | AJ       | HOLZER, M., ET AL., Activation of Mitogen-Activated Protein Kinase Cascade and Phosphorylation of Cytoskeletal Proteins After Neurone-Specific Activation of P21RAS. II. Cytoskeletal Proteins and Dendritic Morphology, Neuroscience, 2001, Page(s) 1041-1054, Volume 105, Number 4, Elsevier Science Ltd., Great Britain |                |
|                    | AK       | SCHMETSDORF, STEFANIE, ET AL., Expression of cell cycle-related proteins in developing and adult mouse hippocampus, International Journal of Developmental Neuroscience, 2005, Page(s) 101-112, Volume 23, Elsevier Ltd.   |                |
|                    | AL       | UEBERHAM, U., ET AL., Letter to Neuroscience Connective Tissue Growth Factor in Alzheimer's Disease, Neuroscience, 2003, Page(s) 1-6, Volume 116, Elsevier Science Ltd on behalf of IBRO   |                |
|                    | AM       | UEBERHAM, UWE, ET AL., Cyclin C expression is involved in the pathogenesis of Alzheimer's disease, Neurobiology of Aging, 2003, Page(s) 427-435, Volume 24, Elsevier Science Inc.  |                |
|                    | AN       | UEBERHAM, UWE, ET AL., The Expression of Cell Cycle Proteins in Neurons and its Relevance for Alzheimer's Disease, Current Drug Targets - CNS & Neurological Disorders, 2005, Page(s) 293-306, Volume 4, Bentham Science Publishers Ltd.   |                |

|                    |                     |                 |            |
|--------------------|---------------------|-----------------|------------|
| Examiner signature | /Stacey Macfarlane/ | Date Considered | 07/24/2008 |
|--------------------|---------------------|-----------------|------------|

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>2</sup> Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).